iMedicus.ca

T1D Glycemic Management Across the Lifespan

Watch the on demand webinar on the new Diabetes Canada Guidelines on Glycemic Management in T1D

Arrhythmia Update 2026 (AU26)

What is iMedicus?

iMedicus is Canada’s most innovative livestream CME channel for specialists and family physicians!

upcoming

September 24, 2025

Live Dinner Sept 24 in Calgary: T1D Glycemic Management Across the Lifespan

Join in Calgary for the new Diabetes Canada Guidelines on Glycemic Management in T1D

Arrhythmia Update Conference (AU26) - February 19-20, 2026

featured

11:26

Diabetes Update 2022 Podcast Series

Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology

59:51

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD

5 hours

Pearls for primary Care virtual conference - October 24, 2025

Pearls for primary Care 2025

03:02

AIM-LO: Statins + Ezetimibe

03:37

AIM-LO: LDL-C: Lower for Longer is Better

06:18

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data

03:03

AIM-LO: Icosapent ethyl (IPE)

06:14

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action

03:14

AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients

04:48

AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for

Engaging With Your Patients about Selection of Injectable Therapies for LDL-C Reduction

on demand

59:51

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in CKD

5 hours

Pearls for primary Care 2025

T1D Glycemic Management Across the Lifespan

Dive into the new Diabetes Canada Guidelines on Glycemic Management in T1D

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs

03:02

AIM-LO: Statins + Ezetimibe

03:37

AIM-LO: LDL-C: Lower for Longer is Better

06:18

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data

03:03

AIM-LO: Icosapent ethyl (IPE)

06:14

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action

03:14

AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients

listen now

11:26

Diabetes Update 2022 Podcast Series

Let’s Be Friends: A Collaborative Conversation between Endocrinology and Cardiology

Diabetes Update 2023 Podcast Series

Optimal Treatment of Lipids: Who and When?

Diabetes Update 2023 Podcast Series

Is it Time to look at Time in Range?

Diabetes Update 2022 Podcast Series

Exploring Treatment Strategies for Diabetic Kidney Disease

11:59

Diabetes Update 2022 Podcast Series

Early Initiation of GLP-1RAs in the Continuum of Care

12:45

Diabetes Update 2022 Podcast Series

Management of Type I Diabetes in Pregnancy

13:33

Diabetes Update 2022 Podcast Series

Incorporating Novel Cardiovascular (Cv) Risk Reduction Strategies for Diabetes Patients: W

11:47

Diabetes Update 2022 Podcast Series

Does IT make a difference?

T1D Glycemic Management Across the Lifespan

Arrhythmia Update 2026 (AU26)

What is iMedicus?

upcoming

Live Dinner Sept 24 in Calgary: T1D Glycemic Management Across the Lifespan

Arrhythmia Update Conference (AU26) - February 19-20, 2026

featured

Diabetes Update 2022 Podcast Series

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C

Pearls for primary Care 2025

AIM-LO: Statins + Ezetimibe

AIM-LO: LDL-C: Lower for Longer is Better

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data

AIM-LO: Icosapent ethyl (IPE)

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action

AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients

AIM-LO: Engaging With Your Patients about Selection of Injectable Therapies for

on demand

A Nephro and Cardio Convo: Common Clinical Questions around Anticoagulation in C

Pearls for primary Care 2025

T1D Glycemic Management Across the Lifespan

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Dosing FAQs

AIM-LO: Statins + Ezetimibe

AIM-LO: LDL-C: Lower for Longer is Better

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Efficacy & Safety Data

AIM-LO: Icosapent ethyl (IPE)

AIM-LO: PCSK9 inhibition (mAbs and siRNA) - Mechanisms of Action

AIM-LO: Key Tips to Maximize Therapeutic Access for Your Patients

listen now

Diabetes Update 2022 Podcast Series

Diabetes Update 2023 Podcast Series

Diabetes Update 2023 Podcast Series

Diabetes Update 2022 Podcast Series

Diabetes Update 2022 Podcast Series

Diabetes Update 2022 Podcast Series

Diabetes Update 2022 Podcast Series

Diabetes Update 2022 Podcast Series

Top 3 Conundrums in HF Podcasts (Spotify)

Top 3 Conundrums in HF Podcasts (Apple Podcasts)